The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
27
No.
17
April 27, 2001
- NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.
- HHS Forms Patient Safety Task Force; Henry Ford Health System Receives $40M.
- UPCI Recruits Shin To Lead Head & Neck Cancer Program.
- Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.
- Possible Association Between Agent Orange, AML, IOM Says.
CCL
Vol.
24
No.
4
April 27, 2001
- Promising Results For Glivec In CML Continue, FDA Grants Priority Review
- High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I
- Wilms’ Tumor Survivors At High Risk Of Heart Failure
- Cancer Pain Treatment Guide Published By NCCN, ACS
- Without Advance Directives, Families Prolong Treatment
- Long-Term Estrogen Use May Increase Ovarian Cancer Risk
- Natural Substance Blocks Androgen Activity In Vitro
- NCI-Approved Clinical Trials Listed For Month Of March
TCL
Vol.
27
No.
18
May 04, 2001
- Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.
- H. Lee Moffitt Cancer Designated A Comprehensive Cancer Center By NCI.
- DeMets Receives Lectureship On Epidemiology From NIH.
- Generic Paclitaxel Approval Withstands Court Challenge.
- Obit: J. Gale Katterhagen, NCAB’s First Community Physician.
- NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.
- FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.
- M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.
- Genetronics Phase II Trials For Head & Neck Completed.
- Biomira Ends Agreement On Lymphoma Vaccine.
TCL
Vol.
27
No.
19
May 11, 2001
- Death On Saltz Regimen Prompt Groups To Suspend Accrual On Colon Cancer Trials.
- Norton Succeeds Einhorn As ASCO President, Colorado’s Paul Bunn Is President-Elect.
- Vermont Cancer Center’s NCI Core Grant Renewed.
- Pharmacia Letter Announces Suspension Of Two Trials.
- Medicare Expands Coverage for Lymphedema Pumps.
- Newest NIH Institute, NIBIB, Gets An Acting Director.
TCL
Vol.
27
No.
20
May 18, 2001
- ASCO Annual Meeting Attendance Tops 25,000, Continuing Fast Growth.
- Lung Cancer Gets Less Press, Study Finds
- Vanderbilt Wins Lung Cancer SPORE Grant.
- Vanderbilt, Jonsson Centers Win NCI SPORE Grants.
- Prevention Trials Should Get More Funding, Coltman Says.
- FDA Approves Gleevec In 73 Days, A Speed Record.
- Pesticides Not Linked To High Rates Of Breast Cancer.
TCL
Vol.
27
No.
21
May 25, 2001
- Appropriators Ask What Happens After NIH Budget-Doubling Ends In FY2004.
- California Cancer Research Program Seeks Non-Resident Survivor Reviewers.
- Emory, Children’s Strengthen Ties
- ASPO Honors Gritz.
- NCI To Place 20% Cap On Grant Renewal Increases.
- NCI Begins Phase III Trial Of Shark Cartilage In NSCLC.
- NIGMS Forms Bioinformatics, Computational Bio Center.
CCL
Vol.
24
No.
5
May 25, 2001
- Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors
- Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer
- Gleevec Approval Sets Record For FDA Review: 73 Days
- Advances Found In Treatment Of Aerodigestive Cancers
- Silicone Implants Not Linked To Increased Risk Of Death
- B-14 Trial: No Advantage To 10 Years Of Tamoxifen
- NCI-Approved Clinical Trials Listed For April 2001
TCL
Vol.
27
No.
22
June 01, 2001
- DeVita, Seffrin Present Cancer Czar PlanTo Feinstein, Without Committee Sign-Off
- Varmus, Branscomb Win Public Service Award From NSF; NCI Clarifies Plans For Large R01s
- President’s Cancer Panel: NCI’s Approach “Paying Off,” Thompson Tells Cancer Panel
- NCI Clarifies Plan For Review Of Epidemiologic Research
- Clinical Trials: For ER+ Breast Cancer, Post-Tamoxifen, NSABP Testing Aromasin In Large Trial
- Oncology Management: US Oncology To Conduct Up To 5 Studies Of PG-TXL In Colorectal, Lung Cancers
- Deals & Collaborations: UAB To Evaluate Firm’s Prostate Cancer Treatment
- Emerging Technologies: Company To Expand Program Studying Polymer Platinates